Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Unregistered Sales of Equity Securities

Cocrystal Pharma, Inc. (OTCBB:COCP) Files An 8-K Unregistered Sales of Equity Securities

Story continues below

Item 3.02 Unregistered Sales of Equity Securities.

On April 20, 2017, Cocrystal Pharma, Inc. (the Company) closed on
proceeds of $3,000,000 in a private placement offering of
12,500,000 shares of the Companys common stock at a purchase
price of $0.24 per share to three accredited investors, which
included Chairman Dr. Raymond F. Schinazi and OPKO Health, Inc.,
of which the Companys director Dr. Phillip Frost is Chairman and
Chief Executive Officer.

The Company intends to use the net proceeds of the offering for
working capital and general corporate purposes. The form of
Securities Purchase Agreement is attached as Exhibit 10.1 to this
Form 8-K and is incorporated herein by reference.

All of the securities were issued and sold in reliance upon the
exemption from registration contained in Section 4(a)(2) of the
Securities Act of 1933 (the Act) and Rule 506 promulgated
thereunder. These securities may not be offered or sold in the
United States in the absence of an effective registration
statement or exemption from the registration requirements under
the Act. The investors are accredited investors and there was no
general solicitation.

Item 9.01 Financial Statements and Exhibits

Exhibit No. Exhibit
10.1 Form of Securities Purchase Agreement

About Cocrystal Pharma, Inc. (OTCBB:COCP)

Cocrystal Pharma, Inc., formerly Biozone Pharmaceuticals, Inc., is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus. The polymerase inhibitors include both nucleosides (Nucs) and non-nucleosides. Its platform consists of computation, medicinal chemistry, click chemistry and X-ray crystallography. The Company determines the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide its design. The Company uses computational methods to screen and design product candidates using its cocrystal structural information.

Cocrystal Pharma, Inc. (OTCBB:COCP) Recent Trading Information

Cocrystal Pharma, Inc. (OTCBB:COCP) closed its last trading session down -0.017 at 0.230 with 10,790 shares trading hands.

An ad to help with our costs